Related Experiment Videos
Neoadiuvant Treatment With Intravesical Interleukin-2 for Recurrent Superficial Transitional Bladder Carcinoma
Marco Grasso1, Fabrizio Torelli, Giuseppe Scannapieco
1Departments of Urology, Desio Hospital and San Raffaele Institute, Milan, Italy.
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|July 13, 2001
Summary
This study investigated interleukin-2 (IL-2) for superficial bladder cancer. While IL-2 showed no direct effect on tumors, it reduced the recurrence rate, suggesting potential for immuno-prophylaxis.
Area of Science:
- Oncology
- Immunology
- Urology
Background:
- Superficial transitional bladder carcinoma is a common malignancy.
- Recurrence is a significant challenge in managing bladder cancer.
- Interleukin-2 (IL-2) is a cytokine with known immunomodulatory effects.
Purpose of the Study:
- To assess the direct impact of intra-vesical recombinant IL-2 on superficial transitional bladder carcinoma.
- To evaluate the effect of IL-2 treatment on the recurrence rate of bladder cancer.
Main Methods:
- A study involving 27 patients with recurrent superficial transitional bladder carcinoma.
- Neoadjuvant treatment with intra-vesical instillation of recombinant IL-2.
- Transurethral resection was performed in conjunction with IL-2 treatment.
Main Results:
- No direct anti-neoplastic effect of IL-2 was observed on the tumors.
- The observed recurrence rate was lower than anticipated based on historical data.
- Intra-vesical IL-2 treatment may influence the immune response against bladder cancer.
Conclusions:
- Intra-vesical IL-2 does not appear to have a direct cytotoxic effect on bladder neoplasms.
- IL-2 treatment may confer a degree of immuno-prophylaxis, reducing cancer recurrence.
- Further research is warranted to explore the immunomodulatory mechanisms of IL-2 in bladder cancer prevention.